Stocks · Healthcare · Biotechnology
Parabilis Medicines, Inc. PBLS
$30.28 -0.53% Close, Oct 2, 2026 · NASDAQ · Market cap $3.53B
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The company holds net cash of $1.04B (cash above total debt).
- The stock is 27% below its highest close of the past year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 42%
How cheap the shares are relative to earnings, cash flow and their own history.
Strength and persistence of the price trend, including versus the S&P 500.
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 5%
- Consecutive EPS beatsBottom 20%
- Upside to consensus price targetBottom 36%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 29%
- Maximum drawdown, 3 yearsTop 4%
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Return on invested capital | -8.7% | — | Top 42% |
Quality of earnings and balance sheet
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Based on the four quarters through Jun 30, 2026 (filed Aug 13, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 0 of 1
- Average EPS surprise, last 4
- -100.0%
- Average 2-day reaction, last 8
- -4.7%
- Positive 20 days after report
- 0 of 1
Analysts
- Consensus price target
- $40.00
- Target vs current price
- +32.1%
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 13, 2026 | -1306.1% | -4.7% | +10.5% | -2.9% | — |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | -$2.32 | -$0.17 | -1306.1% | $100,000 |
| May 19, 2026 | -$0.72 | — | — | — |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- 50-day average slope (20 days)
- +7.2%
- Distance from 50-day average
- -16.6%
- RSI (14)
- 35.8
- Relative volume
- 0.75×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 69.0%
- Current drawdown from 1-year high
- -27.4%
- Maximum drawdown, 3 years
- -27.4%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Sep 18, 2026 | Oct 2, 2026 | -27.4% | 10 days | Not yet recovered |
| Jun 10, 2026 | Jun 15, 2026 | -20.8% | 3 days | 26 days (Jul 23, 2026) |
| Aug 19, 2026 | Sep 15, 2026 | -13.6% | 18 days | 3 days (Sep 18, 2026) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $3.53B
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $0 | $0 |
| Gross profit | $0 | $0 |
| Operating income | -$126.1M | -$152.1M |
| Net income | -$117.9M | -$145.9M |
| EPS (diluted) | -$83.48 | -$92.40 |
| Q1 2025 | Q2 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $148,000 |
| Net income | -$38.3M | -$34.8M | -$45.3M | -$52.5M |
| EPS (diluted) | -$23.84 | -$0.36 | -$34.58 | -$2.32 |
| FY 2024 | FY 2025 | |
|---|---|---|
| Operating cash flow | -$103.6M | -$123.7M |
| Capital expenditure | -$879,000 | -$306,000 |
| Free cash flow | -$104.5M | -$124.0M |
| Dividends paid | $0 | $0 |
| Net share buybacks | $78.1M | $67.5M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $1.12B
- Total assets
- $1.18B
- Total liabilities
- $127.5M
- Total debt
- $47.5M
- Net debt
- -$1.04B
- Shareholders’ equity
- $1.05B
As of Jun 30, 2026 (filed Aug 13, 2026).
Short interest
- Shares sold short
- 6,092,212
- Days to cover
- 13.25
- Change vs previous report
- +10.4%
FINRA short interest, settlement date Sep 15, 2026.